BACKGROUND: Early response to induction chemotherapy is used in current European guidelines to evaluate the efficacy of chemotherapy and subsequently to adapt treatment in pediatric patients with rhabdomyosarcoma (RMS). However, existing literature on the prognostic value of early radiologic response on survival is contradictory; here the prognostic value is analyzed with data from the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor 95 (MMT-95) study. METHODS: This study examined 432 Intergroup Rhabdomyosarcoma Study Grouping III (macroscopic residue) patients enrolled in the SIOP MMT-95 study with a response assessment after 3 courses of chemotherapy (a 2-dimensional assessment). Patients with progressive disease (PD) after 3 courses of chemotherapy were excluded (n 5 7). Failure-free survival (FFS) and overall survival (OS), calculated with the Kaplan-Meier method, were compared for 3 groups (complete response [CR]/partial response [PR], objective response [OR], and no response [NR]). The prognostic impact of early response was assessed through the calculation of Cox proportional hazards. RESULTS: After 3 courses of chemotherapy, 85.2% of the patients had CR/PR, 8.6% had OR, and 6.3% had NR. For all patients, the 5-year FFS and OS rates were 60% (95% confidence interval [CI], 56%-65%) and 74% (95% CI, 70%-78%), respectively. However, a Cox proportional hazards regression analysis revealed no significant difference in FFS or OS between the response groups. The adjusted hazard ratios for an OR and NR were 1.09 (95% CI, 0.63-1.88) and 0.81 (95% CI, 0.39-1.67), respectively, for FFS and 0.91 (95% CI, 0.47-1.76) and 1.27 (95% CI, 0.61-2.64), respectively, for OS. CONCLUSIONS: No evidence was found for the idea that early radiologic response to chemotherapy is prognostic for survival for patients with RMS. Treatment adaptation based on early response (except for patients with PD) should, therefore, no longer be incorporated into future studies.
INTRODUCTION
Early response to induction chemotherapy is used as a prognostic factor for several pediatric malignancies, such as Ewing sarcoma, neuroblastoma, and acute lymphoblastic leukemia. [1] [2] [3] Under the assumption that early response is also prognostic for outcomes in children with localized rhabdomyosarcoma (RMS), the European Pediatric Soft Tissue Sarcoma Study Group RMS-2005 protocol (recruitment closed in December 2016) required a tumor volume reduction of at least one-third for the continuation of treatment with first-line chemotherapy. 4 Patients with a lesser response were switched to second-line chemotherapy.
However, the prognostic value of early radiologic response was questioned by Burke et al. 5 In an analysis of the Intergroup Rhabdomyosarcoma Study IV (IRS-IV) cohort (1991-1997) based on radiologic response at week 8, no evidence of a difference in failure-free survival (FFS) was found. Rosenberg et al 6 came to the same conclusion on the basis of an analysis of the data of the Children's Oncology Group (COG) D9803 cohort (1999) (2000) (2001) (2002) (2003) (2004) (2005) , in which the radiologic response was assessed at week 12.
Dantonello et al 7 analyzed the prognostic value of early radiologic response for survival with data for 529 patients with embryonal RMS treated in 5 consecutive German Cooperative Soft Tissue Sarcoma (CWS) trials , and they found no response (NR) to induction chemotherapy to be associated with a poor outcome. However, the latter study, in contrast to the 2 North American studies, included patients with progressive disease (PD) at the first response evaluation.
Because of the ambiguity in the literature and the fact that radiologic response is still used to adapt treatment for pediatric patients in European study protocols, we aimed to evaluate its prognostic value for survival in a cohort of consecutive patients uniformly treated and included in the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor 95 (MMT-95) study cohort.
MATERIALS AND METHODS
Patients included in this retrospective analysis were treated in the SIOP MMT-95 trial. This trial, performed in 13 countries between July 1995 and June 2003, comprised 2 parts: a randomized trial for patients with high-risk localized RMS who were 6 months to 18 years old and a registration study standardizing treatment for all other RMS patients who were less than 18 years old. Informed consent was obtained from all parents or patients, or both, according to the research ethics requirements of the individual institution. The outline of the study protocol and the results of the randomized part have been described previously 8 ; patients with high-risk nonmetastatic RMS were eligible for randomization to treatment with either vincristine, ifosfamide, and dactinomycin (IVA) or a 6-drug therapy with IVA plus carboplatin, epirubicin, and etoposide. Standard and high-risk patients in the registration study with an incompletely resected tumor or biopsy only (Intergroup Rhabdomyosarcoma Study Group III [IRSG-III] tumor) received IVA chemotherapy except for patients with nodal involvement or patients younger than 3 years with a parameningeal tumor; these patients were systematically allocated to the 6-drug therapy.
All patients received 3 courses of chemotherapy, after which the tumor response was assessed at week 8. The decision on local therapy, by surgery and/or radiotherapy, was based on the response to chemotherapy and the resectability of the residual tumor (delayed surgery). Radiotherapy was delivered after week 17 to patients with an incomplete response after chemotherapy with or without surgery, except for patients aged 3 years or older with parameningeal disease and patients with less than partial response (PR) after 3 courses of 6-drug chemotherapy, who received radiotherapy at week 9, regardless of the response. The recommended dose was 45 Gy, and the target volume was based on the residual tumor volume plus the standard margin except for parameningeal tumors, for which the initial tumor volume was targeted.
The response was assessed with radiologic imaging techniques comparable to those used at diagnosis (computed tomography and/or magnetic resonance imaging) by radiologists at local sites. The tumor response was grouped according to the World Health Organization criteria, which are based on 2-dimensional measurements. 9 A complete response (CR) was defined in the protocol as the complete disappearance of the tumor on radiologic imaging, and PR was defined as a 50% decrease in the tumor area and no new lesions. Objective response (OR) was defined as a decrease of 25% to 50%. NR was defined as a <25% decrease and a < 25% increase in the tumor area. PD was defined as a 25% increase in the tumor area. Because the MMT-95 protocol distinguishes between patients with less or more than PR to determine the necessity of treatment alteration, patients with CR or PR were grouped in a sufficient response (SR) group. Patients with less than PR (ie, OR, NR, or PD) after 3 courses of IVA were switched to 6-drug chemotherapy, and those with less than PR after 3 courses of 6-drug therapy were further treated off protocol.
Patients were included in this analysis if the diagnosis was confirmed by a central pathology review, the tumor was classified as IRSG-III, and a response assessment was performed after 3 courses of chemotherapy. Patients with PD at the time of the response evaluation were excluded because early tumor progression on therapy is known to be associated with a poor outcome. 10 Overall survival (OS) was defined as the time from the start of treatment to death from any cause, and FFS was defined as the time from the start of treatment to disease progression, a second malignancy, or death. Outcomes for living patients were censored at the time of their last reported contact. 
Statistical Analysis
Data from patients included in the randomized study were combined with data from those who were only registered and received standard treatment because the randomized part of the SIOP MMT-95 study revealed no difference in survival between treatment arms. 8 The 5-year FFS and OS were obtained with Kaplan-Meier estimators.
11 A log-rank test was used to compare the FFS and OS levels between the 3 groups. In addition, the prognostic value of early radiologic response for FFS and OS was further assessed with univariate and multivariate Cox proportional hazards regression analyses. After checking the proportional hazards assumption, we investigated the following variables as potential confounders: histology, size, site, nodal status, age at diagnosis, radiotherapy, and delayed surgery. These variables were chosen on the basis of earlier studies identifying these factors as prognostic for survival for pediatric patients with localized RMS. [12] [13] [14] The potential confounders were added one by one to the model. Variables were incorporated into the model if the regression coefficient of the principal determinant, radiologic response, changed more than 10% after the addition of the variable to the model. P values lower than .05 were considered statistically significant.
RESULTS

Patient Population
The MMT-95 cohort contained 626 IRS-III patients, 432 of whom were included in this analysis. The reasons for exclusion are listed in Figure 1 . The cohort contained 7 patients with PD at the first response assessment, and they were excluded (2 of the 7 patients died within 5 years). The median age at diagnosis was 5.0 years (range, 0.3-17.8 years), and the median follow-up time for survivors was 99 months (range, 3-198 months). Induction chemotherapy comprised IVA for 232 of the 432 patients (53.7%) and 6-drug chemotherapy for 193 of the 432 patients (44.7%). Patients' characteristics are further described in Table 1 and Supporting Table 1 (see online supporting information).
Response Assessment and Treatment Continuation
After 3 courses of chemotherapy, 368 of the 432 patients (85.2%) had SR (CR, 11.1%; PR, 74.1%), 37 of 432 (8.6%) had OR, and 27 of 432 (6.3%) had NR. Of the 64 patients with less than PR, 40 initially received IVA, and 24 initially received 6-drug chemotherapy. Six patients continued treatment with IVA, 57 patients were further treated with 6-drug chemotherapy, and 1 continued treatment according to the preferences of the local institution.
Early Response and Effect on Survival
For all patients, the estimated 5-year FFS and OS rates were 60% (95% confidence interval [CI], 56%-65%) and 74% (95% CI, 70%-78%), respectively. There was no evidence of differences in FFS or OS for randomized and nonrandomized patients (P for FFS 5 .4 and P for OS 5 .9 [log-rank test]). No significant differences were observed in FFS or OS according to early response ( Fig.  2A,B ). For patients with embryonal histology, the 5-year FFS rate was 62% (95% CI, 56%-68%) for SR (n 5 243), 71% (95% CI, 55%-88%) for OR (n 5 28), and 74% (95% CI, 52%-96%) for NR (n 5 17). Among patients with alveolar RMS, the 5-year FFS rate was 57% (95% CI, 48%-65%) for SR (n 5 125), 22% (95% CI, 0%-49%) for OR (n 5 9), and 60% (95% CI, 30%-90%) for NR (n 5 10). No significant differences in FFS were observed on the basis of early response in embryonal patients (P 5 .4 [log-rank test]) or alveolar patients (P 5 .1 [log-rank test]; Table 2) A Cox proportional hazards regression analysis did not show early radiologic response as a significant prognostic factor for survival. Unadjusted hazard ratios for OR and NR were 1.01 (95% CI, 0.59-1.71) and 0.71 (95% CI, 0.35-1.45), respectively, for FFS and 0.97 (95% CI, 0.51-1.85) and 1.17 (95% CI, 0.57-2.39), respectively, for OS. Adjusted for histology, tumor size, tumor site, nodal involvement, age, radiotherapy, and postchemotherapy surgery, the hazard ratios for OR and NR were 1.09 (95% CI, 0.63-1.88) and 0.81 (95% CI, 0.39-1.67), respectively, for FFS and 0.91 (95% CI, 0.47-1.76) and 1.27 (95% CI, 0.61-2.64), respectively, for OS.
Burden of Therapy
The burden of local therapy for the primary tumor in patients who survived is summarized in Table 3 . Among the 307 survivors, 137 (44.6%) underwent secondary surgery to obtain local control; 126 patients (92%) had conservative surgery (without important long-term functional/cosmetic consequences), 2 patients (1.6%) had major surgery without functional/cosmetic consequences, and 2 patients (1.6%) had mutilating surgery (both patients had an SR after induction chemotherapy). Further information on surgical margins, radiotherapy fields, and dosages is provided in Supporting Figure 1 and Supporting Tables 3 and 4 (see online supporting information).
DISCUSSION
The vast majority of IRSG-III RMS patients (>85%) included in the SIOP MMT-95 study showed a very good response (at least PR) to induction chemotherapy; however, in this study, we found no evidence that early radiologic response, in terms of tumor size reduction, was prognostic for survival.
These findings are consistent with 2 consecutive COG studies in which no significant difference in 5-year FFS was observed based on early response. 5, 6 In the first analysis by Burke et al 5 of a cohort of 444 consecutive patients with localized RMS who were enrolled in the IRS-IV trial, the 5-year FFS rate was 75% for patients with CR, 71% for patients with PR, and 78% for patients with NR. No significant difference in FFS was observed between the groups (P 5 .57). In a similar analysis performed with data (n 5 338) from the COG D9803 study, the 5-year FFS rate was 74% for patients with CR, 75% Abbreviations: GU, genitourinary; N0, no evidence of lymph node involvement; N1, evidence for lymph node involvement; T1, tumor confined to the organ or tissue of origin; T2, tumor not confined to the organ or tissue of origin.
for patients with PR, and 64% for patients with NR; again, no significant difference in FFS was observed between the response groups (P 5 .49).
What could be the reason that early radiologic response did not prove to be prognostic for survival in both COG studies and our study? First, the measurement of the radiologic response is subject to important interobserver and intra-observer variability, as demonstrated in previous studies. 15, 16 The interobserver variability could (potentially) lead to different treatment decisions in more than 10% of patients, as observed in a retrospective study by Schoot et al. 17 Second, although some tumor masses do not show radiologic response, there might be other changes in response to therapy, such as the maturation of rhabdomyoblasts. Several small studies have suggested that patients with persistent mature rhabdomyoblasts at the end of therapy do not have an impaired prognosis. 18, 19 Furthermore, the radiologic response may not reflect actual tumor necrosis. 20, 21 In contrast to our study, Dantonello et al 7 found early response to induction chemotherapy to be an important prognostic factor for survival in an analysis of data from 529 patients with embryonal RMS treated in 5 consecutive CWS trials . In their study, the authors compared the outcomes of patients with PR and patients with NR; the latter group also included patients with PD. The risk ratio of NR to PR was 2.0 (95% CI, 1.3-3.2). The same conclusion was drawn by Ferrari et al 22 in a retrospective single-center analysis of 108 RMS patients in which a multivariate analysis indicated a tumor response to be a significant prognostic factor for survival.
Comparing the results of our study with those of the COG studies and the studies of Dantonello et al 7 and Ferrari et al 22 is difficult because the study populations, initial treatments, measurements of response, definitions of response, and treatments after response assessment all differed. However, in contrast to our study and both COG studies, patients with PD at the time of response assessment were included in the studies of Ferrari et al and Dantonello et al. A study by Minn et al 10 showed that the prognosis for patients with PD was poor, and including these patients in the group of patients with a poor response (<33% tumor response) might explain the inferior outcomes for this group. Ferrari et al and Dantonello et al included patients treated over a period of more than 20 years; as a result, the included patients were treated differently, and also cruder imaging methods were used to assess the response to induction chemotherapy. In the study by Ferrari et al, the radiologic response was measured as a continuous variable in contrast to our study and the other mentioned studies, in which the response was assessed categorically. Although measuring tumor response as a continuous variable increases the statistical power, these continuous measurements are not applicable in clinical practice.
In the SIOP MMT-95 study, the radiologic response was measured by the local radiologists, and this possibly confounded our results; a central review of radiologic imaging could lead to more consistent measurements and hence treatment decisions. Moreover, the MMT-95 protocol contained treatment modifications based on the response measurement, and this potentially influenced our results. Although the MMT-95 randomized trial showed no difference in effectiveness between the IVA and 6-drug arms, it might be that the intensified 6-drug chemotherapy was more effective than standard IVA in the patients with less than PR (n 5 64); however, 29 of 64 patients were not switched to a different treatment regimen. Besides the modifications to chemotherapy, decisions regarding local treatment were also partly based on the response to chemotherapy. 8 Specifically, more patients in favorable subgroups in SIOP MMT studies did not receive radiotherapy in comparison with studies by other collaborative groups, and this treatment strategy potentially confounded our analysis because certain patients, on the basis of the tumor site and the tumor response, did not receive radiotherapy. 23 Nevertheless, we found no significant difference in survival based on the response after we had divided the SR subgroup into patients with CR (patients with CR and a tumor located at specific sites did not receive radiotherapy) and patients with PR (Supporting Table 2 [see online supporting information]).
We realize that historically the reason to switch chemotherapy in patients with less than PR was based not solely on the assumption that response is prognostic for survival but also on the assumption that further reduction in tumor volume might reduce the extent of subsequent local therapy. However, we did not find differences in the number of patients with mutilating surgery or in the radiotherapy dose and targeted area based on the response. The therapeutic decisions concerning radiotherapy fields and dosages (ie, radiotherapy on the residual tumor vs the initial volume) depended not on the response to chemotherapy but rather on the tumor site; however, a larger residual tumor resulted in a larger radiotherapy field (Supporting Figure 1 and Supporting Table 3 [see online supporting information]).
In conclusion, on the basis of this study and the COG studies, we propose that future phase 3 trials should include a switch in chemotherapy only for patients with PD at early response assessment. All other patients should continue firstline chemotherapy. We are uncertain whether our findings also apply to phase 2 trials, in which patients generally have relapsed or refractory disease and patterns of tumor response might not be comparable with the response seen in previously chemotherapy-naive patients. Nevertheless, all phase 3 trials conducted by SIOP MMT or COG, adding a promising chemotherapeutic agent to standard backbone therapy yielded no improvement in survival in comparison with standard therapy. 8, 12, 24, 25 Therefore, we advocate that future phase 3 trials focus on the efficacy of functional imaging techniques, such as diffusion-weighted magnetic resonance imaging and fludeoxyglucose positron emission tomography, to determine early response, although preliminary results are conflicting. 20, [26] [27] [28] [29] Furthermore, for consistency and standardization of response measurements and subsequent treatment decisions, we emphasize the importance of the use of standardized imaging protocols and central radiology review as part of future trials. 
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